AstraZeneca PLC is a global biopharmaceutical company formed by the 1999 merger of Astra AB and Zeneca Group. In FY2025, AstraZeneca reported $58.739 billion in total revenue, $10.233 billion in profit for the year, and approximately 89,900 employees.
AstraZeneca Key Facts
- Formed in 1999 through the merger of Astra AB and Zeneca Group.
- Headquarters: Cambridge, England.
- CEO: Sir Pascal Soriot.
- FY2025 total revenue: $58.739 billion.
- FY2025 profit for the year: $10.233 billion.
- FY2025 employees: approximately 89,900.
How AstraZeneca Makes Money
AstraZeneca earns most of its revenue from patented prescription medicines, supported by alliance and collaboration revenue. Its main therapy areas include oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare disease.
FY2025 Strategic Context
AstraZeneca's FY2025 growth was driven by broad therapy-area momentum and pipeline delivery. The key risks are patent cliffs, pricing pressure, regulatory outcomes, China exposure, and whether late-stage pipeline programs can sustain growth toward the company's long-range goals.
